{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:25:07Z","timestamp":1787034307622,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Epidemiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pharmacovigilance is the science and practice aimed at detecting, assessing, understanding, and preventing adverse drug events (ADEs). During the COVID-19 pandemic, a wide range of medications - suchasantivirals, corticosteroids, anticoagulants, immunomodulators, and sedatives - were used during respiratorysupport. Reports of hepatotoxicity, cardiotoxicity, renal impairment, and neurological effects underscored the need for systematic safety monitoring. Since 2012, our research group has been monitoring the clinical use of various prescriptions at the National Institute of Infectious Diseases in Brazil. In this study, we aimed to evaluate factors associated with adverse drug events in hospitalized COVID-19 patients,with emphasis on ICU management practices, polypharmacy and fentanyl exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This observational study was conducted between March and September 2021 and included patients with a positive molecular test for SARS-CoV-2. Sociodemographic characteristics, including age, sex, educational level, and family income, as well as medical history such as hypertension, diabetes, obesity, dyslipidemia, fever, cough, dyspnea, and anosmia, were collected. Clinical data on hospitalizations, commonly prescribed medications, length of stay in intensive care units, vaccination status, oxygen supplementation, type of respiratory support, deaths, and oxygen saturation were also recorded. All adverse reactions were classified using a validated algorithm and standard terminology, and patients were followed until discharge or death. Data were initially collected on paper forms and subsequently entered into an electronic data capture platform. Associations between patient characteristics, treatments, and adverse reactions were analyzed using Poisson regression, with statistical significance set at\n                      <jats:italic>p<\/jats:italic>\n                      -value &amp;lt; 0.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 113 patients, 110 experienced at least one adverse event, totaling 411 events. The mean age was 56.5 years; 54.9% were male, 53.1% had hypertension, 28.3% had diabetes, 22.2% had received at least one vaccine dose, and 17.7% died. Higher rates of adverse events were observed among intubated patients and those who received fentanyl, which is commonly used during the intubation process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, intubation and fentanyl use were associated with higher rates of ADEs. These findings should be interpreted cautiously given the severity of illness, ICU sedation practices, and the possibility of confounding by indication. Therefore, active pharmacovigilance strategies may contribute to improved medication safety in critically ill populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fepid.2026.1770145","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:36:25Z","timestamp":1787031385000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse drug events in hospitalized COVID-19 patients: a pharmacovigilance perspective on ICU management and fentanyl exposure"],"prefix":"10.3389","volume":"6","author":[{"given":"Michele Ferreira","family":"Murgel","sequence":"first","affiliation":[{"name":"Evandro Chagas National Institute of Infectious Diseases (INI), FIOCRUZ","place":["Rio de Janeiro, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"de Souza Borges Quintana","sequence":"additional","affiliation":[{"name":"Evandro Chagas National Institute of Infectious Diseases (INI), FIOCRUZ","place":["Rio de Janeiro, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Olmo","family":"Pinheiro","sequence":"additional","affiliation":[{"name":"Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation","place":["Rio de Janeiro, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edtor Santos","family":"da Silva","sequence":"additional","affiliation":[{"name":"Evandro Chagas National Institute of Infectious Diseases (INI), FIOCRUZ","place":["Rio de Janeiro, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia Luciana","family":"dos Santos Moura","sequence":"additional","affiliation":[{"name":"Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation","place":["Rio de Janeiro, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"da Gama Oliveira","sequence":"additional","affiliation":[{"name":"Evandro Chagas National Institute of Infectious Diseases (INI), FIOCRUZ","place":["Rio de Janeiro, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia Maria Valete","family":"Rosalino","sequence":"additional","affiliation":[{"name":"Evandro Chagas National Institute of Infectious Diseases (INI), FIOCRUZ","place":["Rio de Janeiro, Brazil"]},{"name":"Department of Otorhinolaryngology and Ophthalmology, Federal University of Rio de Janeiro (UFRJ)","place":["Rio de Janeiro, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto Marcelo","family":"Sperandio da Silva","sequence":"additional","affiliation":[{"name":"Evandro Chagas National Institute of Infectious Diseases (INI), FIOCRUZ","place":["Rio de Janeiro, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40292-022-00506-96","article-title":"Hypertension and COVID-19: current evidence and perspectives","volume":"29","author":"Gallo","year":"2022","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2022","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.21270\/archi.v11i2.5780","article-title":"Perfil de seguran\u00e7a e efic\u00e1cia cl\u00ednica da azitromicina no tratamento da COVID-19: revis\u00e3o da literatura","volume":"11","author":"Cachoni","year":"2022","journal-title":"Arch Health Invest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ajic.2019.06.023","article-title":"A systematic risk-based strategy to select personal protective equipment for infectious diseases","volume":"48","author":"Jones","year":"2020","journal-title":"Am J Infect Control"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e351516","DOI":"10.47820\/recima21.v3i5.1516","article-title":"Implica\u00e7\u00f5es de doen\u00e7as cardiovasculares relacionadas \u00e0 infec\u00e7\u00e3o por COVID-19: revis\u00e3o integrativa","volume":"3","author":"Sousa","year":"2022","journal-title":"RECIMA21 - Rev Cient Multidisc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.36660\/abc.20200209","article-title":"COVID-19 e o cora\u00e7\u00e3o","volume":"114","author":"Strabelli","year":"2020","journal-title":"Arq Bras Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"954359","DOI":"10.3389\/fphar.2022.954359","article-title":"Adverse drug events in the prevention and treatment of COVID-19: a data mining study on the FDA adverse event reporting system","volume":"13","author":"Guo","year":"2022","journal-title":"Front Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"938552","DOI":"10.3389\/fphar.2022.93855214","article-title":"Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system","volume":"13","author":"Jeong","year":"2022","journal-title":"Front Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"707386","DOI":"10.3389\/fnins.2021.707386","article-title":"COVID-19 pandemic and fentanyl use disorder in African Americans","volume":"15","author":"Blackwood","year":"2021","journal-title":"Front Neurosci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e00245820","DOI":"10.1590\/0102-311X00245820","article-title":"Rea\u00e7\u00f5es adversas a medicamentos em pacientes com COVID-19 no Brasil: an\u00e1lise das notifica\u00e7\u00f5es espont\u00e2neas do sistema de farmacovigil\u00e2ncia brasileiro","volume":"37","author":"Melo","year":"2021","journal-title":"Cad Sa\u00fade P\u00fablica"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e00237221","DOI":"10.1590\/0102-311X0023722117","article-title":"Notifica\u00e7\u00e3o de eventos adversos de medicamentos no Brasil: perfil dos profissionais que notificam ao sistema de farmacovigil\u00e2ncia brasileiro","volume":"37","author":"Melo","year":"2021","journal-title":"Cad Sa\u00fade P\u00fablica"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.26633\/RPSP.2022.166","article-title":"Eventos adversos no sistema nervoso centralpotencialmente relacionados aos medicamentos utilizados na COVID-19: revis\u00e3o de escopo","volume":"46","author":"Mello","year":"2022","journal-title":"Rev Panam Salud Publica"},{"key":"B13","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1128\/AAC.02842-14","article-title":"A clinical adverse drug reaction prediction model for patients with Chagas disease treated with Benznidazole","volume":"58","author":"Sperandio Da Silva","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B15","volume-title":"The WHO Adverse Reaction Terminology\u2014WHO-ART","year":"2005"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41440-020-00535-8","article-title":"Reninangiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study","volume":"43","author":"Matsuzawa","year":"2020","journal-title":"Hypertens Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ajic.2020.06.213","article-title":"Prevalence of comorbidities among individuals with COVID-19: a rapid review of current literature","volume":"49","author":"Bajgain","year":"2021","journal-title":"Am J Infect Control"},{"key":"B18","doi-asserted-by":"publisher","first-page":"780872","DOI":"10.3389\/fendo.2022.780872","article-title":"Association of obesity with COVID-19 severity and mortality: an updated systemic review, meta-analysis, and meta-regression","volume":"13","author":"Singh","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e210032","DOI":"10.1590\/1981-22562020023.210032","article-title":"Hesita\u00e7\u00e3o vacinal e os desafios para enfrentamento da pandemia de COVID-19 em idosos no brasil","volume":"23","author":"Souto","year":"2021","journal-title":"Rev Bras Geriatr Gerontol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.51234\/aben.20.e02.c15","article-title":"Seguran\u00e7a do paciente idoso relacionada \u00e0 terap\u00eautica medicamentosa no tratamento da COVID-19","volume-title":"Enfermagemgerontologica no Cuidado do Idoso em Tempos da COVID 19","author":"Galiza","year":"2020"},{"key":"B21","volume-title":"Polifarmacia y Factoresasociadoseneltratamiento de la COVID-19 en Adultos de LaUrbanizaci\u00f3n San Germ\u00e1n - La Victoria \u2013 Lima - 2022","author":"Lipa Chavez","year":"2023"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s11739-020-02509-7","article-title":"Early predictors of in-hospital mortality in patients with COVID-19 in a large American cohort","volume":"15","author":"Bahl","year":"2020","journal-title":"Intern Emerg Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100055","DOI":"10.1016\/j.lanwpc.2020.100055","article-title":"Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: a nationwide observational study","volume":"4","author":"Sim","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"B24","doi-asserted-by":"publisher","first-page":"12634","DOI":"10.34117\/bjdv8n2-278","article-title":"Sedation used in the treatment of COVID-19 in adult patients in intensive care: systematic review","volume":"8","author":"Martins","year":"2022","journal-title":"Braz J Dev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e416101321371","DOI":"10.33448\/rsd-v10i13.21371","article-title":"Comparative analysis of sedative consumption during ICU stay COVID-19","volume":"10","author":"Vieira","year":"2021","journal-title":"Res Soc Dev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e70101623236","DOI":"10.33448\/rsd-v10i16.23236","article-title":"Drug induced liver injury in hospitalized patients","volume":"10","author":"Gon\u00e7alves","year":"2021","journal-title":"Res Soc Dev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0731-7085(83)80038-7","article-title":"Drug effects on clinical laboratory tests","volume":"1","author":"Siest","year":"1983","journal-title":"J Pharm Biomed Anal"}],"container-title":["Frontiers in Epidemiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fepid.2026.1770145\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:36:26Z","timestamp":1787031386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fepid.2026.1770145\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":27,"alternative-id":["10.3389\/fepid.2026.1770145"],"URL":"https:\/\/doi.org\/10.3389\/fepid.2026.1770145","relation":{},"ISSN":["2674-1199"],"issn-type":[{"value":"2674-1199","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1770145"}}